


# Estrella Immunopharma, Inc. (Thu, Jun 27, 2024)

Hold candidate since Jun 26, 2024

Gain 1.09%

StockInvest.us  
Gyneju st. 14, "ROCKIT"  
Vilnius, LT-01109  
Lithuania



score: **-0.238**

#/ 54252

Trend: Sell  
MV Long: Sell  
MV Short: Buy  
Pivot: Buy  
Volume: Buy  
MACD: Buy

## Tech commentaries:

The **Estrella Immunopharma, Inc.** stock price gained **1.09%** on the last trading day (Thursday, 27th Jun 2024), rising from **\$0.92** to **\$0.93**. During the last trading day the stock fluctuated **14.12%** from a day low at **\$0.85** to a day high of **\$0.97**. The price has fallen in 6 of the last 10 days but is still up by **0.49%** over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **15 thousand** more shares were traded than the day before. In total, **24 thousand** shares were bought and sold for approximately **\$22.63 thousand**.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall **-22.88%** during the next 3 months and, with a 90% probability hold a price between **\$0.605** and **\$0.752** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

A buy signal was issued from a pivot bottom point on **Tuesday, June 18, 2024**, and so far it has risen 14.53%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). **Estrella Immunopharma, Inc.** has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. The very low volume increases the risk and reduces the other technical signals issued. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **Estrella Immunopharma, Inc.** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at **\$0.97**. On a fall, the stock will find some support from the short-term average at **\$0.91**. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

**Estrella Immunopharma, Inc.** finds support from accumulated volume at **\$0.93** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance from accumulated volume at **\$1.03**, **\$1.05** and **\$1.07**.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved **\$0.120** between high and low, or **14.12%**. For the last week, the stock has had daily average volatility of **9.93%**.

**Estrella Immunopharma, Inc.** holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

**Risk: Medium**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.